MA54223B1 - 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR CANCER TREATMENT - Google Patents
2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR CANCER TREATMENTInfo
- Publication number
- MA54223B1 MA54223B1 MA54223A MA54223A MA54223B1 MA 54223 B1 MA54223 B1 MA 54223B1 MA 54223 A MA54223 A MA 54223A MA 54223 A MA54223 A MA 54223A MA 54223 B1 MA54223 B1 MA 54223B1
- Authority
- MA
- Morocco
- Prior art keywords
- pyridin
- pyrrolo
- dihydro
- derivatives
- cancer treatment
- Prior art date
Links
- QDSJMVZVUSYEMY-UHFFFAOYSA-N 2,3-dihydropyrrolo[3,4-c]pyridin-1-one Chemical class N1=CC=C2C(=O)NCC2=C1 QDSJMVZVUSYEMY-UHFFFAOYSA-N 0.000 title abstract 2
- 102100028199 Mitogen-activated protein kinase kinase kinase kinase 1 Human genes 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 101001059991 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 1 Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 101100177670 Caenorhabditis elegans hpk-1 gene Proteins 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 108010002838 hematopoietic progenitor kinase 1 Proteins 0.000 abstract 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La présente invention concerne des dérivés de 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one de formule générale (i) et des sels pharmaceutiquement acceptables de ceux-ci, utilisés en tant qu'inhibiteurs de kinase progénitrice hématopoïétique 1 (hpk1), r1, r1a, r2, r3, r4 et (r5)a étant tels que définis dans la description, des compositions pharmaceutiques comprenant de tels composés et et des compositions pour le traitement d'une croissance cellulaire anormale, y compris le cancer. Un exemple particulier du composé est, par exemple, 4-[(méthylamino)méthyl]-6- [méthyl(propan-2-yl)amino]-2-[6-(4-propyl-4h-l,2,4-triazol-3-yl) pyridin-2-yl]-2,3-dihydro-lh-pyrrolo[3,4-c]pyridin-l-one. La présente invention concerne la préparation de composés donnés à titre d'exemple ainsi que des données pharmacologiques de ceux-ci (par exemple des pages 82 à 211; exemples 1 à 188; tableaux 1 à 5).The present invention relates to 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives of general formula (i) and pharmaceutically acceptable salts thereof, used as inhibitors of hematopoietic progenitor kinase 1 (hpk1), r1, r1a, r2, r3, r4 and (r5)a being as defined in the description, pharmaceutical compositions comprising such compounds and and compositions for the treatment of cell growth abnormal, including cancer. A particular example of the compound is, for example, 4-[(methylamino)methyl]-6-[methyl(propan-2-yl)amino]-2-[6-(4-propyl-4h-1,2,4 -triazol-3-yl)pyridin-2-yl]-2,3-dihydro-lh-pyrrolo[3,4-c]pyridin-l-one. The present invention relates to the preparation of exemplary compounds as well as pharmacological data thereof (e.g. pages 82 to 211; Examples 1 to 188; Tables 1 to 5).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862767602P | 2018-11-15 | 2018-11-15 | |
| PCT/IB2019/059702 WO2020100027A1 (en) | 2018-11-15 | 2019-11-12 | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA54223A MA54223A (en) | 2022-02-23 |
| MA54223B1 true MA54223B1 (en) | 2023-10-31 |
Family
ID=77369712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA54223A MA54223B1 (en) | 2018-11-15 | 2019-11-12 | 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR CANCER TREATMENT |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR117073A1 (en) |
| MA (1) | MA54223B1 (en) |
-
2019
- 2019-11-12 MA MA54223A patent/MA54223B1/en unknown
- 2019-11-14 AR ARP190103343A patent/AR117073A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA54223A (en) | 2022-02-23 |
| AR117073A1 (en) | 2021-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551117A1 (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| US6617331B2 (en) | Purine inhibitors of protein kinases, G proteins and polymerases | |
| Domagala | Structure-activity and structure-side-effect relationships for the quinolone antibacterials | |
| MA30412B1 (en) | Pharmaceutical Compounds | |
| Kumar et al. | Synthesis and in vitro anti-tubercular evaluation of 1, 2, 3-triazole tethered β-lactam–ferrocene and β-lactam–ferrocenylchalcone chimeric scaffolds | |
| MA34903B1 (en) | AZAINDAZOLE OR DIAZAINDAZOLE DERIVATIVES AS MEDICAMENTS | |
| MA28064A1 (en) | Pyrrolo [3,4-c] pyrazole derivatives active as kinase inhibitors | |
| CA2455181A1 (en) | Benzimidazo[4,5-f]isoquinolinone derivatives | |
| TNSN08270A1 (en) | PYRIMIDIC DERIVATIVES FOR TREATING ABNORMAL CELL GROWTH | |
| MA26991A1 (en) | TRIAZOLOPYRIDINES AS ANTI-INFLAMMATORY AGENTS | |
| BRPI0713253A2 (en) | pde4 inhibition method, method of treating a pde4-mediated disease, compound and pharmaceutical composition | |
| HUP0303721A2 (en) | Imidazolyl derivatives as corticotropin releasing factor inhibitors, process for their preparation and pharmaceutical compositions containing them | |
| HUP0402352A2 (en) | Pyrimidine derivatives for use as phosphodiesterase (pde)7 inhibitors and pharmaceutical compositions containing them | |
| CA2687265A1 (en) | P70 s6 kinase inhibitors | |
| MA27716A1 (en) | 4-aminopyrimidine-5-ONE | |
| RU2007110629A (en) | DNA-PC INHIBITORS | |
| MA31170B1 (en) | 2-AMINO-5,7-DIHYDRO-6H-PYRROLO [3,4-D] PYRIMIDINE DERIVATIVES AS INHIBITORS OF HSP-90 FOR THE TREATMENT OF CANCER | |
| MA28742B1 (en) | PYRIDO-PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION | |
| HUP0301032A2 (en) | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases, their use and pharmaceutical compositions containing them | |
| MA50069B1 (en) | 1-(4-(ISOXAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPAN-2-OL DERIVATIVES AND SIMILAR COMPOUNDS AS IL-7 AND IFN-GAMMA INHIBITORS FOR THE TREATMENT OF DISEASES AUTOIMMUNE AND CHRONIC INFLAMMATION | |
| HUP0203422A2 (en) | Imidazole derivatives as phosphodiesterase vii inhibitors, process for their preparation and pharmaceutical compositions containing them | |
| AU2022271244A1 (en) | Shp2 inhibitor monotherapy and uses thereof | |
| MX2023003631A (en) | Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same. | |
| MA54223B1 (en) | 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR CANCER TREATMENT | |
| KR940009184A (en) | Pyrazole condensed ring derivatives, preparation method thereof and androgen inhibitor |